|
Oct 8
|
Virios Therapeutics Transforms into Dogwood Therapeutics
|
|
Oct 7
|
Virios Therapeutics Enters Into Definitive Merger Agreement With Wex Pharmaceuticals
|
|
Oct 7
|
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
|
|
Aug 13
|
VIRI: Enrollment Complete in Phase 2a Long COVID Trial; Results Expected in October 2024…
|
|
Jul 23
|
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
|
|
May 13
|
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript
|
|
May 13
|
VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24…
|
|
May 9
|
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 2
|
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
|
|
Mar 26
|
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
|
|
Nov 14
|
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript
|
|
Nov 13
|
VIRI: Provides Overview of Phase 3 Program in Fibromyalgia
|
|
Nov 13
|
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
|
|
Aug 14
|
Virios Therapeutics Announces Halt to At-The-Market Offering Sales
|
|
Aug 12
|
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcript
|
|
Aug 10
|
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
|
|
Aug 9
|
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
|
|
Apr 25
|
Virios Therapeutics Shares Almost Double In Trading Session - Here's Why
|
|
Apr 24
|
Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
|